Characteristics of the subjects
| Number of patients | 98 | |
| Age (mean ± SD, range, y) | 62.7 ± 9.8 (30-80) | |
| Sex (male/female) | 76/22 | |
| Smoking history | Missing = 15 | |
| Never-smoked | 17 | |
| Ex-smoker (quit >1 y before diagnosis) | 12 | |
| Current smoker | 54 | |
| Histology | ||
| ADC | 41 | |
| BAC | 6 | |
| SQC | 40 | |
| NSCLC | 11 | |
| ADC +BAC vs. non-ADC | 47 vs. 51 | |
| Gefitinib treatment | ||
| First-line therapy | 4 | |
| Second-line therapy | 44 | |
| Third-line therapy | 45 | |
| Fourth-line therapy | 5 | |
| Response to gefitinib | Evaluable patients = 80 | |
| PR | 20 (25%) | |
| SD | 18 (22.5%) | |
| PD | 42 (52.5%) | |
| Number of patients | 98 | |
| Age (mean ± SD, range, y) | 62.7 ± 9.8 (30-80) | |
| Sex (male/female) | 76/22 | |
| Smoking history | Missing = 15 | |
| Never-smoked | 17 | |
| Ex-smoker (quit >1 y before diagnosis) | 12 | |
| Current smoker | 54 | |
| Histology | ||
| ADC | 41 | |
| BAC | 6 | |
| SQC | 40 | |
| NSCLC | 11 | |
| ADC +BAC vs. non-ADC | 47 vs. 51 | |
| Gefitinib treatment | ||
| First-line therapy | 4 | |
| Second-line therapy | 44 | |
| Third-line therapy | 45 | |
| Fourth-line therapy | 5 | |
| Response to gefitinib | Evaluable patients = 80 | |
| PR | 20 (25%) | |
| SD | 18 (22.5%) | |
| PD | 42 (52.5%) | |
Abbreviations: ADC, adenocarcinoma; BAC, bronchiolo-alveolar cell carcinoma; SQC, squamous cell carcinoma; PR, partial remission; SD, stable disease; PD, progressive disease.